Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...

An estimated 5,000 people in the United States are living with Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

You could have an underlying medical condition, such as nasal polyps. Also, it’s best to talk with a doctor if you have severe or concerning symptoms. They may want to perform tests to rule out ...

Sinusitis, commonly known as a sinus infection, occurs when the nasal cavities become infected, swollen, and inflamed. While it is typically caused by viruses, bacteria or fungi can also trigger the ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation and ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications.The ...

could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been shown to reduce symptoms. Sanofi ...

Nasal microbiota transplantation could revolutionise the treatment of chronic rhinosinusitis and respiratory tract infections. Learn more!

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...